AR125219A1 - Anticuerpo monoclonal o fragmento de unión al antígeno del mismo que se une específicamente al gd2 (gangliósido gd2), y uso del mismo - Google Patents
Anticuerpo monoclonal o fragmento de unión al antígeno del mismo que se une específicamente al gd2 (gangliósido gd2), y uso del mismoInfo
- Publication number
- AR125219A1 AR125219A1 ARP220100720A ARP220100720A AR125219A1 AR 125219 A1 AR125219 A1 AR 125219A1 AR P220100720 A ARP220100720 A AR P220100720A AR P220100720 A ARP220100720 A AR P220100720A AR 125219 A1 AR125219 A1 AR 125219A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- amino acid
- acid sequence
- group
- sequence selected
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención se refiere al campo de la biotecnología y la medicina, en particular a un anticuerpo monoclonal o fragmento de unión al antígeno del mismo que se une específicamente al GD2 (gangliósido GD2). La invención se refiere además a ácidos nucleicos que codifican dicho anticuerpo, vectores de expresión, células huésped y métodos para producirlos, métodos para producir los anticuerpos según la invención, composiciones farmacéuticas que comprenden el anticuerpo según la invención, composiciones farmacéuticas que comprenden el anticuerpo según la invención y otros compuestos terapéuticamente activos, métodos para tratar enfermedades o trastornos mediados por GD2, usos de los anticuerpos o composiciones farmacéuticas de los mismos para tratar enfermedades o trastornos mediados por GD2, y usos de los anticuerpos y otros compuestos terapéuticamente activos para tratar enfermedades o trastornos mediados por GD2. Reivindicación 1: Un anticuerpo monoclonal aislado o un fragmento de unión al antígeno del mismo que se une específicamente al GD2 (gangliósido GD2), caracterizado por que comprende: (a) un dominio variable de la cadena pesada que comprende: (i) CDR1 con una secuencia aminoácida seleccionada del grupo de la SEQ ID Nº 1 o SEQ ID Nº 2, (ii) CDR2 con la secuencia aminoácida de la SEQ ID Nº 3, (iii) CDR3 con una secuencia aminoácida seleccionada del grupo de la SEQ ID Nº 4, SEQ ID Nº 5, SEQ ID Nº 6 o SEQ ID Nº 7; y (b) un dominio variable de la cadena ligera que comprende: (i) CDR1 con una secuencia aminoácida seleccionada del grupo de la SEQ ID Nº 8 o SEQ ID Nº 9, (ii) CDR2 con una secuencia aminoácida seleccionada del grupo de la SEQ ID Nº 10 o SEQ ID Nº 11, (iii) CDR3 con una secuencia aminoácida seleccionada del grupo de la SEQ ID Nº 12 o SEQ ID Nº 13.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2021107773A RU2796937C2 (ru) | 2021-03-24 | Моноклональное антитело или его антигенсвязывающий фрагмент, которое специфически связывается с gd2 (ганглиозид gd2), и его применение |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR125219A1 true AR125219A1 (es) | 2023-06-28 |
Family
ID=83395963
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220100720A AR125219A1 (es) | 2021-03-24 | 2022-03-25 | Anticuerpo monoclonal o fragmento de unión al antígeno del mismo que se une específicamente al gd2 (gangliósido gd2), y uso del mismo |
Country Status (9)
| Country | Link |
|---|---|
| CN (1) | CN117677695A (es) |
| AR (1) | AR125219A1 (es) |
| CL (1) | CL2023002843A1 (es) |
| CO (1) | CO2023012549A2 (es) |
| CR (1) | CR20230456A (es) |
| EC (1) | ECSP23072412A (es) |
| TW (1) | TW202304989A (es) |
| UY (1) | UY39687A (es) |
| WO (1) | WO2022203552A1 (es) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005070967A2 (en) * | 2004-01-22 | 2005-08-04 | Merck Patent Gmbh | Anti-cancer antibodies with reduced complement fixation |
| US9315585B2 (en) * | 2010-06-19 | 2016-04-19 | Memorial Sloan Kettering Cancer Center | Anti-GD2 antibodies |
| KR102207859B1 (ko) * | 2013-03-15 | 2021-01-27 | 메모리얼 슬로안 케터링 캔서 센터 | 고 친화도 항-gd2 항체 |
-
2022
- 2022-03-24 TW TW111111114A patent/TW202304989A/zh unknown
- 2022-03-24 UY UY0001039687A patent/UY39687A/es unknown
- 2022-03-24 CN CN202280024459.8A patent/CN117677695A/zh active Pending
- 2022-03-24 WO PCT/RU2022/050096 patent/WO2022203552A1/en active Application Filing
- 2022-03-24 CR CR20230456A patent/CR20230456A/es unknown
- 2022-03-25 AR ARP220100720A patent/AR125219A1/es unknown
-
2023
- 2023-09-22 EC ECSENADI202372412A patent/ECSP23072412A/es unknown
- 2023-09-22 CO CONC2023/0012549A patent/CO2023012549A2/es unknown
- 2023-09-25 CL CL2023002843A patent/CL2023002843A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ECSP23072412A (es) | 2023-10-31 |
| CL2023002843A1 (es) | 2024-03-22 |
| CR20230456A (es) | 2023-12-13 |
| CN117677695A (zh) | 2024-03-08 |
| TW202304989A (zh) | 2023-02-01 |
| UY39687A (es) | 2022-08-31 |
| WO2022203552A1 (en) | 2022-09-29 |
| CO2023012549A2 (es) | 2023-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR126019A1 (es) | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación | |
| AR110017A1 (es) | Anticuerpos de pd-1 y usos de estos | |
| PE20221580A1 (es) | Anticuerpos terapeuticos y sus usos | |
| PE20181952A1 (es) | Anticuerpos anti-ll-33, composiciones, metodos y usos de los mismos | |
| BR112020015479A2 (pt) | Anticorpos anticlaudina 18.2 e usos dos mesmos | |
| FI3484915T3 (fi) | Uusia zikavirusepitooppeihin spesifisesti sitoutuvia vasta-aineita ja niiden käyttöjä | |
| RU2019118359A (ru) | Антитело к cd73 человека | |
| US20220332816A1 (en) | Anti-tigit antibodies | |
| JP2020529863A (ja) | 抗ｒｏｒ１抗体とその作製及び使用方法 | |
| JP2012518425A5 (es) | ||
| PE20191079A1 (es) | Inmunoglobulinas y usos de estas | |
| PE20210554A1 (es) | Anticuerpos anti-cxcr5 y composiciones y usos de los mismos | |
| AR123480A1 (es) | Moléculas de unión terapéuticas | |
| PE20231080A1 (es) | Anticuerpos que se unen a cd3 y cd19 | |
| PE20230464A1 (es) | Union de anticuerpos multiespecificos a bcma | |
| AR124084A1 (es) | ANTICUERPOS DE CADENA PESADA QUE SE UNEN AL RECEPTOR a DE FOLATO | |
| RU2019134462A (ru) | Антитела, связывающиеся с steap-1 | |
| RU2016141285A (ru) | Биспецифические антигенсвязывающие полипептиды | |
| AR125219A1 (es) | Anticuerpo monoclonal o fragmento de unión al antígeno del mismo que se une específicamente al gd2 (gangliósido gd2), y uso del mismo | |
| US20210371514A1 (en) | Materials and methods for treating stress-related disorders and cancer | |
| AR125040A1 (es) | Constructos anti-vista y usos de estos | |
| AR127271A1 (es) | Anticuerpos biespecíficos que se unen específicamente a cd47 y cd20, y usos de los mismos | |
| PE20240895A1 (es) | Anticuerpos del receptor antitransferrina y usos de los mismos | |
| US20210317216A1 (en) | Anti-flt3 antibodies and compositions | |
| CA3216468A1 (en) | Vhh polypeptides that bind to interleukin 6 (il-6), compositions and methods of use thereof |